Thera-SAbDab

APLITABART

> Structural Summary

Therapeutic	Aplitabart
Target	TNFRSF10B/CD262/DR5/TRAILR2
Heavy Chain	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMSWVRQAPGKGLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGDSMITTDYWGQGTLVTVSS
Light Chain	DIQMTQSPSSLSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSYRTFGQGTKVEIK
100% seqID Fv Structure	None
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

There are currently no PDB structures close in sequence to this therapeutic Fv. Click here to build a model with ABodyBuilder2.

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder2
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole IgM+J Chain (Cyclic Pentamer)
Isotype	M3
Highest Clinical Trial (Feb '25)	Phase-I
Estimated Status (Feb '25)	Active
Recorded Developmental Technology
INN Year Proposed	2024
INN Year Recommended	2024
Companies Involved	IgM Biosciences
Conditions Approved	na
Conditions Active	Colorectal cancer, Non-Hodgkin's lymphoma, Solid tumours
Conditions Discontinued	Acute myeloid leukaemia
Notes	IgM Version of Tigatuzumab (same Fv sequence)

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy